Currently, there are 386.00M common shares owned by the public and among those 340.85M shares have been available to trade.
The company’s stock has a 5-day price change of 11.31% and -10.07% over the past three months. MRNA shares are trading -14.55% year to date (YTD), with the 12-month market performance down to -59.16% lower. It has a 12-month low price of $29.25 and touched a high of $170.47 over the same period. MRNA has an average intraday trading volume of 10.76 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.34%, -7.71%, and -54.13% respectively.
Institutional ownership of Moderna Inc (NASDAQ: MRNA) shares accounts for 70.86% of the company’s 386.00M shares outstanding.
It has a market capitalization of $13.67B and a beta (3y monthly) value of 1.83. The earnings-per-share (ttm) stands at -$9.28. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.07% over the week and 8.37% over the month.
Earnings per share for the fiscal year are expected to decrease by -5.85%, and 23.78% over the next financial year. EPS should grow at an annualized rate of 14.97% over the next five years, compared to -42.94% over the past 5-year period.
Looking at the support for the MRNA, a number of firms have released research notes about the stock. Barclays stated their Equal Weight rating for the stock in a research note on February 18, 2025, with the firm’s price target at $111-$45. Goldman coverage for the Moderna Inc (MRNA) stock in a research note released on January 29, 2025 offered a Neutral rating with a price target of $51. Argus was of a view on December 18, 2024 that the stock is Hold, while BofA Securities gave the stock Underperform rating on December 10, 2024, issuing a price target of $41. Berenberg on their part issued Hold rating on November 19, 2024.
